PTX Target Price Revision – H.C Wainwright & Co
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing...
Humankind has been trying to find a cure for cancer for thousands of years. Today,...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...
Prescient Therapeutics has entered a collaboration with Carina Biotech to develop new targeted cell therapies...
Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019...
With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) develops personalised medicines as potential...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.